Home
Neuraxpharm

Neuraxpharm Market Share Analysis for June 2026

neuraxpharm is a leading european specialty pharmaceutical company focused on the treatment of central nervous system (cns) disorders.

Health > Biotechnology and Pharmaceuticals

Domainneuraxpharm.de

Year Founded1985

Employees1001 - 5000

Annual Revenue$500M - $1B

Neuraxpharm

Neuraxpharm (including company regionals)

neuraxpharm.de

See more website traffic and engagement information

Neuraxpharm Revenue up to June 2026 is 500M - 1B

revenue generated by Neuraxpharm top domains

Neuraxpharm top domains revenue over 3 years

Revenue for Neuraxpharm top domains

neuraxpharm.de500M - 1B

See more with Sales Intelligence

Total visits to Neuraxpharm's top domains

Understand Neuraxpharm market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Neuraxpharm's top domains

Analyze Neuraxpharm engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Neuraxpharm's top domains

See how Neuraxpharm keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Neuraxpharm top competitors by domain

Top similar sites in June 2026, ranked by their affinity

betapharm.deCompany NamebetapharmEmployees1001 - 5000HQGermany, AugsburgAnnual revenue$200M - $500MTotal visits1.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Neuraxpharm

These are the website technologies, by industry, used by Neuraxpharm top domains

Content Management System (4)

WordPress

Widget (4)

Twemoji

Advertising (3)

DoubleClick

Email Services (3)

Microsoft Exchange Online

More Technologies

10

See all

News & Signals from Neuraxpharm

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNeuraxpharm launches sales of medical cannabis extracts.Medical cannabis producer Panaxia Labs Israel Ltd. (TASE: PNAX), a subsidiary of Panaxia Global (TASE: PNAX) and Neuraxpharm, a European company that specializes in the central nervous system have launched sales of medical cannabis extracts under the joint Brand: Naxiva-Panaxol in Germany.

NewsNeuraxpharm partners with Panaxia Pharmaceutical Industries Ltd..CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.

NewsNeuraxpharm hires Dan Furrer as Head of Corporate Marketing.Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the appointment of Dan Furrer as Head of Corporate Marketing.